News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
291,294 Results
Type
Article (16527)
Company Profile (283)
Press Release (274484)
Section
Business (82803)
Career Advice (296)
Deals (14037)
Drug Delivery (43)
Drug Development (51547)
Employer Resources (58)
FDA (6053)
Job Trends (5574)
News (150383)
Policy (10992)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1024)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (22333)
ALS (61)
Alzheimer's disease (903)
Antibody-drug conjugate (ADC) (89)
Approvals (6065)
Artificial intelligence (119)
Autoimmune disease (14)
Automation (5)
Bankruptcy (118)
Best Places to Work (4892)
BIOSECURE Act (8)
Biosimilars (49)
Biotechnology (233)
Bladder cancer (46)
Brain cancer (21)
Breast cancer (150)
Cancer (1356)
Cardiovascular disease (120)
Career advice (254)
Career pathing (5)
CAR-T (108)
Cell therapy (314)
Cervical cancer (8)
Clinical research (41692)
Collaboration (514)
Compensation (231)
Complete response letters (13)
COVID-19 (1196)
CRISPR (38)
C-suite (147)
Cystic fibrosis (77)
Data (1421)
Denatured (11)
Depression (30)
Diabetes (137)
Diagnostics (1531)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (16)
Drug discovery (82)
Drug pricing (37)
Drug shortages (6)
Duchenne muscular dystrophy (85)
Earnings (31177)
Editorial (19)
Employer branding (9)
Employer resources (51)
Events (49471)
Executive appointments (413)
FDA (6707)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (487)
Gene editing (91)
Generative AI (9)
Gene therapy (241)
GLP-1 (389)
Government (1360)
Grass and pollen (2)
Guidances (19)
Healthcare (7221)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (84)
Indications (18)
Infectious disease (1267)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (22)
Intellectual property (59)
Interviews (39)
IPO (7557)
IRA (14)
Job creations (985)
Job search strategy (228)
Kidney cancer (6)
Labor market (8)
Layoffs (218)
Leadership (5)
Legal (1569)
Liver cancer (34)
Lung cancer (190)
Lymphoma (87)
Machine learning (1)
Management (14)
Manufacturing (127)
MASH (49)
Medical device (2947)
Medtech (2948)
Mergers & acquisitions (6795)
Metabolic disorders (394)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (61)
Neuropsychiatric disorders (23)
Neuroscience (1288)
NextGen: Class of 2025 (2278)
Non-profit (1102)
Northern California (1609)
Now hiring (21)
Obesity (202)
Opinion (119)
Ovarian cancer (61)
Pain (43)
Pancreatic cancer (52)
Parkinson's disease (112)
Partnered (9)
Patents (116)
Patient recruitment (70)
Peanut (37)
People (26230)
Pharmaceutical (48)
Pharmacy benefit managers (11)
Phase I (14620)
Phase II (19320)
Phase III (12367)
Pipeline (761)
Podcasts (47)
Policy (49)
Postmarket research (901)
Preclinical (6148)
Press Release (31)
Prostate cancer (61)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (279)
Real estate (1576)
Recruiting (24)
Regulatory (9123)
Reports (20)
Research institute (1034)
Resumes & cover letters (45)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (92)
Series B (61)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1424)
Special edition (13)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (2017)
State (1)
Stomach cancer (4)
Supply chain (21)
Tariffs (4)
The Weekly (35)
United States (12612)
Vaccines (266)
Venture capitalists (28)
Webinars (7)
Weight loss (117)
Women's health (16)
Worklife (3)
Date
Last 7 days (413)
Last 30 days (1555)
Last 365 days (20530)
2025 (5123)
2024 (21268)
2023 (23218)
2022 (31896)
2021 (32631)
2020 (26737)
2019 (17895)
2018 (13051)
2017 (14377)
2016 (12565)
2015 (15033)
2014 (10888)
2013 (7970)
2012 (8031)
2011 (8159)
2010 (7855)
Location
Africa (195)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (18243)
Australia (3069)
California (3642)
Canada (1109)
China (338)
Colorado (140)
Connecticut (146)
Delaware (91)
Europe (39692)
Florida (443)
Georgia (115)
Idaho (16)
Illinois (228)
India (9)
Indiana (92)
Iowa (3)
Japan (76)
Kansas (61)
Kentucky (5)
Louisiana (6)
Maine (14)
Maryland (458)
Massachusetts (2875)
Michigan (74)
Minnesota (142)
Mississippi (1)
Missouri (26)
Montana (14)
Nebraska (4)
Nevada (16)
New Hampshire (16)
New Jersey (926)
New Mexico (13)
New York (997)
North Carolina (536)
North Dakota (4)
Northern California (1609)
Ohio (110)
Oklahoma (9)
Oregon (21)
Pennsylvania (699)
Puerto Rico (3)
Rhode Island (16)
South America (257)
South Carolina (5)
Southern California (1424)
Tennessee (27)
Texas (426)
Utah (50)
Virginia (71)
Washington D.C. (32)
Washington State (334)
Wisconsin (13)
291,294 Results for "rise therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
January 6, 2025
·
2 min read
Press Releases
Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer
January 14, 2025
·
2 min read
Biosimilars
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market.
March 26, 2025
·
6 min read
·
Annalee Armstrong
Deals
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the biotech ecosystem? Experts weigh in.
January 8, 2025
·
3 min read
·
Annalee Armstrong
GLP-1
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself.
March 19, 2025
·
8 min read
·
Ben Hargreaves
Press Releases
Precision Medicine Surge: KFSHRC Achieves 39% Rise in Genetic Mutation Analysis
March 20, 2025
·
2 min read
Press Releases
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
January 29, 2025
·
3 min read
Press Releases
RISE Robotics to be Awarded GUINNESS WORLD RECORDS™ title for Strongest Robotic Arm Prototype
March 13, 2025
·
1 min read
China
The Rise of China Innovation in the Time of Trump
With incoming president Donald Trump threatening a trade war with China, experts told
BioSpace
that the new administration will likely understand why medicines should be treated differently.
January 16, 2025
·
4 min read
·
Annalee Armstrong
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
·
2 min read
·
Tristan Manalac
1 of 29,130
Next
